Skip to main content

Day: February 12, 2026

Mohawk Industries Reports Q4 2025 Results

CALHOUN, Ga., Feb. 12, 2026 (GLOBE NEWSWIRE) — Mohawk Industries, Inc. (NYSE: MHK) today announced fourth quarter 2025 net earnings of $42 million and earnings per share (“EPS”) of $0.68; adjusted net earnings were $124 million, and adjusted EPS was $2.00. Net sales for the fourth quarter of 2025 were $2.7 billion, up 2.4% as reported and down 3.3% on an adjusted basis versus the prior year. During the fourth quarter of 2024, the Company reported net sales of $2.6 billion, net earnings of $90 million and earnings per share of $1.43; adjusted net earnings were $123 million, and adjusted EPS was $1.95. For the twelve months ended December 31, 2025, net earnings and EPS were $370 million and $5.93, respectively; adjusted net earnings were $559 million, and adjusted EPS was $8.96. Net sales for the twelve months of 2025 were $10.8...

Continue reading

DraftKings Reports Fourth Quarter Revenue Growth of 43%

Reported Positive Net Income Set Records for Revenue and Adjusted EBITDA BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced its fourth quarter and fiscal year 2025 financial results. The Company also posted a letter to shareholders and an earnings presentation on the Investor Relations section of its website at investors.draftkings.com. Fourth Quarter 2025 HighlightsFor the three months ended December 31, 2025, DraftKings reported revenue of $1,989 million, an increase of $596 million, or 43%, compared to $1,393 million during the same period in 2024. The increase in the Company’s fourth quarter 2025 revenue was driven primarily by continued healthy customer engagement, efficient acquisition of new customers, and higher Sportsbook net revenue margin. “We closed...

Continue reading

CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent HighlightsTotal revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarter U.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarter Total revenue for 2025 was $56.7 million, an increase of 10% over the prior year Active implanting centers in the U.S. grew to 252 in 2025, as compared to 223 in the prior year Initiated the BENEFIT-HF trial with first enrollments expected...

Continue reading

Perimeter Announces Date for Fourth Quarter and Year End 2025 Earnings Call

CLAYTON, Mo., Feb. 12, 2026 (GLOBE NEWSWIRE) — Perimeter Solutions (NYSE: PRM) (“Perimeter” or the “Company”), a leading provider of industrial products and services that support critical and complex customer missions across a range of niche applications, announced today it will release its financial results for the fourth quarter and year end 2025 on Thursday, February 26, 2026, before the market opens. The Company will host a conference call to discuss these results at 8:30 a.m. ET on the same day. The presentation will be led by CEO Haitham Khouri, CFO Kyle Sable, and Head of Investor Relations Seth Barker. The live webcast of the call can be accessed through Perimeter’s investor relations website at https://ir.perimeter-solutions.com/ and as follows: When: Thursday, February 26, 2026, at 8:30 AM (ET) Dial-in Number: 877-407-9764...

Continue reading

PacBio Announces Fourth Quarter and Full Year 2025 Financial Results

MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results:  Q4 2025 Q4 2024 FY 2025 FY 2024Revenue (in millions) $44.6 $39.2 $160.0 $154.0Consumable revenue (in millions) $21.6 $18.8 $82.0 $70.3Instrument revenue (in millions) $17.3 $15.3 $53.8 $65.8Service and other revenue (in millions) $5.7 $5.1 $24.2 $17.9RevioTM system placements 21 23 61 97VegaTM system placements 42 7 140 7Annualized Revio pull-through per system ~$242,000 ~$240,000 ~$233,000 ~$252,000Ending cash, cash equivalents, and investments(in millions) $279.5 $389.9    Gross margin, operating expenses, net income (loss), and net income (loss) per share are reported on a GAAP and non-GAAP basis....

Continue reading

SPS Commerce Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Company delivers 100th consecutive quarter of topline growth Fourth quarter 2025 revenue grew 13% and recurring revenue grew 14% from the fourth quarter of 2024 Announces planned retirement of Chief Financial Officer and appointment of new Chief Financial Officer Announces increase to Share Repurchase Program  MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) — SPS Commerce, Inc. (NASDAQ: SPSC), the leading intelligent supply chain network, today announced financial results for the fourth quarter and year ended December 31, 2025. Financial Highlights Fourth Quarter 2025 Financial HighlightsRevenue was $192.7 million in the fourth quarter of 2025, compared to $170.9 million in the fourth quarter of 2024, reflecting 13% growth. Recurring revenue grew 14% from the fourth quarter of 2024. Net income was $25.8 million or $0.68 per diluted...

Continue reading

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025. Congenital Hyperinsulinism (HI)In December 2025, Rezolute reported topline results from sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI. The study did not meet its primary or key secondary endpoints.The study demonstrated reductions from baseline in hypoglycemia events by self-monitored blood glucose at both ersodetug dose levels, but reductions were not statistically significant compared to...

Continue reading

Arteris Announces Financial Results for the Fourth Quarter and Full Year 2025 and Estimated First Quarter and Full Year 2026 Guidance

CAMPBELL, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced financial results for the fourth quarter and year ended December 31, 2025 and provided estimated first quarter and full year 2026 guidance. “In the fourth quarter of 2025, we again delivered strong financial results, including a new record of Annual Contract Value plus royalties reaching $83.6 million, representing 28% year-over-year growth. During the quarter, our customers surpassed the milestone of more than four billion systems shipped with SoCs connected by Arteris System IP, and we enjoyed royalty growth of 50% year-over-year,” said K. Charles Janac, President and CEO of Arteris. “As cybersecurity threats intensify not just in software but...

Continue reading

Trupanion Reports Fourth Quarter & Full Year 2025 Results

SEATTLE, Feb. 12, 2026 (GLOBE NEWSWIRE) — Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the fourth quarter and full year ended December 31, 2025. “Since 2021, we’ve delivered more than $500 million in discretionary profit, growing at a 22% CAGR, including over $150 million last year alone,” said Margi Tooth, Chief Executive Officer and President of Trupanion. “In 2025, we achieved our 15% annual margin target, while increasing subscription revenue and reinvesting record profits to drive four straight quarters of higher retention and accelerating gross pet adds. We’re poised to advance confidently into our next strategic plan.”Fourth Quarter 2025 Financial and Business HighlightsTotal revenue was $376.9 million, an increase of 12% compared to...

Continue reading

Flux Power Reports Fiscal Year 2026 Second Quarter Financial Results

VISTA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Flux Power Holdings, Inc. (NASDAQ: FLUX), a leading developer of advanced lithium-ion energy storage solutions and software-driven electrification for commercial and industrial equipment, today reported financial and operational results for the 2026 fiscal second quarter ended December 31, 2025. Second Quarter and Recent Business HighlightsIncreased revenue 7.2% sequentially to $14.1 million Achieved positive GAAP net income for the first time in its history Secured more than $3.6 million in additional purchase orders to support a long-standing airline customer Awarded U.S. Patent for determining the State of Health (SoH) of a battery pack, which uses advanced algorithms for predictive diagnostics to extend the overall battery lifespan Introduced next-gen telematics hardware SkyLNK...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.